Rockwell Medical Inc (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that its new website for Triferic has launched at www.triferic.com. The new website includes extensive product information to educate patients and healthcare providers about Triferic’s unique mode of action and its advantages and clinical benefits over current iron therapy. Triferic is the only FDA approved iron product indicated to replace iron and maintain hemoglobin in hemodialysis patients in the United States. (Original Source)

Shares of Rockwell Medical closed yesterday at $7.71. RMTI has a 1-year high of $18.90 and a 1-year low of $7.09. The stock’s 50-day moving average is $11.04 and its 200-day moving average is $12.22.

On the ratings front, Rockwell Medical has been the subject of a number of recent research reports. In a report issued on September 29, Oppenheimer analyst Ling Wang reiterated a Buy rating on RMTI, with a price target of $26, which represents a potential upside of 237.2% from where the stock is currently trading. Separately, on August 13, Morgan Stanley’s Andrew Berens initiated coverage with a Sell rating on the stock and has a price target of $7.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ling Wang and Andrew Berens have a total average return of -16.3% and 4.1% respectively. Wang has a success rate of 17.3% and is ranked #3689 out of 3755 analysts, while Berens has a success rate of 53.3% and is ranked #1590.

Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.